year left
short interest float
genocea bioscienc gnca clinic stage biotechnolog compani
primarili focus develop neoantigen vaccin candid treat cancer
understand cell recogn target neoantigen uniqu patient tumor
led vc big pharma interest neoantigen therapeut target sever larg
collabor recent announc genocea candid design use
proprietari antigen-select platform atla abl exclus select neoantigen
pre-exist immun respons approach expect
enhanc accuraci efficaci rel compet neoantigen approach util
predict algorithm compani lead candid current test
phase i/iia trial immunogen data expect genocea plan
use atla develop asset pipelin includ
intellig design neoantigen vaccin
one key factor differenti compet neoantigen vaccin
develop composit includ neoantigen measur pre-
exist immun respons therebi increas probabl elicit therapeut
relev immun respons patient addit atla platform uniqu
abil detect neoantigen elicit respons t-cell subset
could lead enhanc vivo efficaci compar method primarili focus
neoantigen approach highlight pharma
partnership develop neoantigen immunotherapi approach gener
signific level interest vc big pharma number
collabor announc includ larg up-front payment equiti invest
mileston payment royalti sale describ greater detail within report
case genocea compani note publicli explor partnership
opportun atla platform base potenti advantag atla
platform believ good chanc collabor emerg
immunogen data phase i/iia trial anticip
genocea conduct multipl proof-of-concept studi across varieti tumor type
demonstr abil atla identifi neoantigen gener measur t-cell
activ independ hla-typ basi posit immune-profil data
compani announc accept ind may follow
initi phase i/iia studi trial consist three part part assess
monotherapi patient evid diseas high risk
relaps part assess combin checkpoint inhibitor patient
stabl diseas partial respons part evalu monotherapi
patient advanc metastat diseas immunogen data part
anticip give insight competit profil atla
immunogen data phase i/iia studi
analyst certif disclosur pleas see page
strong rational combin neoantigen vaccin checkpoint inhibitor efficaci immun
checkpoint inhibitor associ level mutat burden tumor heterogen number tumor
infiltr lymphocyt til one key driver link mutat load checkpoint inhibitor respons
frequenc neoantigen neoantigen vaccin abil activ direct cell toward
highly-specif tumor-associ antigen use preclin shown synerg checkpoint inhibitor
recent patient relaps follow vaccin compet neoantigen-vaccin trial demonstr
complet signific partial respons subsequ checkpoint inhibitor therapi note compet
program use predict algorithm select antigen like less accur approach genocea
howev given likelihood respons low patient popul initi clinic data support
idea neoantigen vaccin augment therapeut effect checkpoint inhibitor therapi
data indic competit advantag atla platform tradit develop predict
algorithm atla technolog like result accur identif neoantigen place
predict tradit in-silico approach contain sever barrier efficaci often util algorithm train
databas limit peptid length captur bind affin data small fraction potenti
antigen addit make predict base singl bind event fail account addit step
antigen process includ proteasom process peptid transport atla platform aim address
underli issu expos antigen-express librari directli autolog antigen-pres cell
mimick antigen present process would happen vivo step interact apc
patient-deriv t-cell allow identif neoantigen elicit relev immun respons
potenti approach demonstr immuno-profil studi compar result atla
netmhcpan current predict algorithm patient variabl tumor type netmhcpan fail predict
true stimul neoantigen true stimul neoantigen identifi
atla addit netmhcpan also shown mischaracter inhibitori neoantigen
second quarter result june genocea cash cash equival
million expect fund oper fourth quarter second quarter compani
amend loan secur agreement hercul capit inc provid million debt financ
form term loan expens million second quarter compar million
second quarter expens million second quarter compar
million period net loss million compar net loss million second
tabl content
therapeut target neoantigen
neoantigen identif atla
clinic data discuss
market inform immuno-oncolog
ici combin therapi develop
atla opportun develop
therapeut vaccin herp
risk invest
clinical-stag biotechnolog compani focus develop neoantigen-bas
therapi treatment cancer neoantigen aris non-synonym mutat within tumor cell
recogn potenti valuabl target treatment cancer one major barrier efficaci
current neoantigen therapi approach proper identif true neoantigen elicit stimulatori immun
respons genocea offer differenti rational approach neo-antigen select proprietari
atla platform immuno-profil studi show tradit predict algorithm netmhcpan fail
predict mani true-neoantigen identifi atla genocea lead asset util atla
select relev neoantigen creat person vaccin consist synthet long peptid pair
poly-iclc patient varieti tumor current evalu phase i/iia studi
immunogen data anticip treatment develop use monotherapi well
combin immun checkpoint inhibitor due scientif rational atla platform form basi
follow asset depict figur gener neo-antigen cancer vaccin preclin
develop august genocea announc initi pre-clin work adopt t-cell
therapi tailor use atlas-target select
lifesci capit compani report
therapeut target neoantigen
well accept tumor evad suppress host immun system exploit number cellular
mechan effort bypass pathway treatment develop stimul drive immun
system better recogn cancer foreign entiti bodi one area focu understand
har therapeut potenti neoantigen produc cancer cell neoantigen non-self-antigen aris
result somat mutat within cancer cell protein recogn foreign non-self
individu immun system lead anti-canc immun respons format appear correl
increas mutat load high frequenc neoantigen format observ cancer mutat
burden somat mutat per megabas respond well checkpoint figur
depict estim neoantigen preval variou human cancer immunoreact neoantigen
identifi domin form immune-system respons compar form tumor-specif
tumor-associ target neoantigen pose signific advantag tradit use tumor-
associ antigen taa recogn t-cell foreign subject central toler
mechan support use neoantigen vaccin cancer higher number neoantigen
melanoma lung cancer bladder overal respond well immunotherapi treatment wherea
lower mutat load glioblastoma aml prostat cancer less respons util genocea
atla platform cancer low high number neoantigen may better target immun system
lead enhanc anti-canc respons
figur preval neoantigen format variou cancer
schumach schreiber
 schreiber neoantigen cancer immunotherapi scienc pp
 et al role neoantigen respons immun checkpoint blockad intern immunolog pp
 et al improv cancer immunotherapi empir neoantigen select trend cancer
approach wide use identifi neoantigen mutation-bas cancer vaccin center creat
algorithm predict model develop stratifi treatment target hand share cancer mutat
individu mutat depict figur
immun activ achiev patient receiv stratifi cancer vaccin clinic trial perform
last decad use model overal lacklust result lack efficaci understood
result heterogen cancer mutat patient cancer type also aris
ingrain problem predict algorithm method built train neural network predict
possibl neoantigen base potenti bind affin variou mhc allel databas use train
network primarili consist peptid mhc molecul preferenti bind addit
algorithm gener limit mhc class molecul predict t-cell respons larg ignor
mhc class ii molecul predict t-cell respons demonstr import gener
effect immun length restrict impos boundari predict power method
et al target heterogen cancer individu neoeptiop vaccin clin cancer
 et al improv peptide-mhc class interact predict integr elut ligand
peptid bind affin data journal immunolog pp
heterogen immun system result differ proteasom antigen process neoepitop transport
t-cell bind overal account construct algorithm factor effect
potenti immun system activ creat weak predict algorithm make difficult identifi
proper number type antigen stimul immun system patient thu transit
begun develop cancer vaccin creat individu treatment address heterogen
cancer mutat patient figur still need incorpor immun system heterogen
patient analysi genocea antigen lead acquisit atla platform take uniqu
approach address problem differenti competitor
atla high-throughput t-cell antigen discoveri platform valid particip unlik
algorithm predict model atla platform identifi neoantigen patient tumor
patient known immun respons antigen identifi compani synthes
person cancer vaccin patient alreadi prime respond therapi gener overview
atla workflow depict figur
two compon atla platform recreat natur immun respons patient
t-cell antigen present machineri gener antigen plasmid librari human immun
system model ex-vivo non-specif expans cell enrich patient-deriv pbmc
differenti monocyt monocyte-deriv dendrit cell mddc autolog
antigen-pres cell tumor exom sequenc allow identif possibl neo-antigen
individu transform coli cell yield antigen-plasmid librari compon use
potenti advantag atla platform mimick t-cell arm human immun system
laboratori set platform identifi individu mutat express patient tumor cell
distinguish specif mutat immuno-stimulatori immuno-inhibitori produc immun respons
determin deliv coli express isol individu put neoantigen patient antigen
present cell apc process present peptid surfac recogn
patient cell analyz t-cell respons platform measur cytokin level trigger
t-cell upon antigen present bind
platform versatil identifi neoantigen also util detect tumor-associ
antigen taa viral-associ antigen vaa cell receptor tcr versatil could lead possibl
partnership compani administ person cancer vaccin combin checkpoint inhibitor
high number tumor infiltr lymphocyt til specif tumor antigen correl respons
checkpoint inhibit use atla platform genocea intend increas number tumor specif
til ultim bypass tumor evas suppress mechan although littl detail provid
compani note publicli explor partnership opportun atla platform
import identifi t-cell respons t-cell possess direct cytotox
tumor cell either direct cell-cel contact mediat secret cytokin tumor cell
constitut express mhc class molecul versu mhc class ii molecul make recogniz
t-cell bind exclus mhc class result much prior neoantigen screen focus
mhc class restrict peptid howev therapeut vaccin base restrict taa shown
margin efficaci may due part lack t-cell respons although cell preferenti
recogn mhc class ii molecul mediat immun restrict mhc type mhc-class
depend counterpart cell shown mediat t-cell respons prime t-
cell initi immun respons well maintain t-cell function secret
essenti growth prolifer t-cell addit sever studi shown
cell acquir vivo cytotox ifn- driven upregul mhc class ii express tumor cell surfac
result cell becom capabl recogn kill mhc class ii express tumor cell
pathway independ t-cell mechan t-cell anti-cancer effect depict
figur import elicit respons neoantigen vaccin support
kol convers lead io physician test neoantigen directli
t-cell deriv patient pbmc genocea atla platform abl detect neoantigen elicit
respons t-cell subset potenti lead increas vivo efficaci compar method focus
elicit t-cell respons
 et al mhc class ii restrict neoantigen promis target tumor immunotherapi cancer letter pp
figur anti-canc effect t-cell
neoantigen hold great promis stimul direct immun respons aris tumor-specif
somat mutat cell recogn antigen undergon thymic select
recogn foreign non-self epitop util antigen produc tumor express
normal cell cancer vaccin design direct drive cell tumor site therebi reduc side
effect associ t-cell attack host tissu genocea atla platform vaccin candid may provid
effect approach drive higher respons rate fewer side effect compar immuno-stimulatori
strategi util clinic compani first neoantigen vaccin candid enter clinic gen-
phase i/iia trial recent began test monotherapi combin therapi
initi immunogen data studi expect step involv vaccin product
whole blood collect pbmc enrich tumor biopsi exom sequenc neoantigen identif
vaccin manufactur summar figur
neoantigen identif atla begin process vaccin gener whole blood
collect patient peripher blood mononuclear cell pbmc enrich use densiti gradient
cell sort non-specif expand monocyt isol
differenti monocyte-deriv dendrit cell mddc autolog antigen present cell apc
compon becom patient human immun system plate coincid biopsi
patient tumor taken whole exom sequenc perform identifi put neoantigen express
tumor antigen encod plasmid librari individu transform coli creat
antigen express librari
 coli ad directli phagocyt human monocyte-deriv dendrit cell mddc depict order
drive mhc antigen present coli librari co-express cytoplasm variant listeriolysin cllo
pore-form cytolysin produc listeria monocytogen also introduc follow acidif
phagolysosom oligomer cllo protein form pore releas content phagolysosom
includ put neoantigen content process proteasom
antigen enter mhc-i process pathway mddc repres patient antigen
process present ex vivo autolog cell recognit measur quantifi
assess concentr releas cytokin interferon gamma ifng
system also use drive mhc-ii antigen present use second coli strain express
cllo figur set content phagolysosom remain vesicl instead
proteolyt process antigen enter mhc-ii process pathway mddc upon recognit
autolog cell immunolog synaps cytokin measur quantifi
ghamsari et al genome-scal neoantigen screen use atla priorit candid antigen
immunotherapi non-smal cell lung cancer patient poster present societi immunotherapi cancer annual
 et al ph-depend perfor macrophag phagosom listeriolysin listeria
monocytogen journal experiment medicin pp
et al role hemolysin intracellular growth listeria monocytogen jounal experiment medicin
et al protein cell antigen method high-throughput identif vaccin
figur mechan antigen present mhc i/ii bacteri neoantigen express librari
neoantigen determin t-cell respons measur patient-specif cytokin threshold
threshold determin use neg control repres coli strain express antigen
recogn immun system stimulatori neoantigen defin result cytokin concentr
greater standard deviat mean median cytokin concentr level across test antigen
inhibitori neoantigen defin result cytokin concentr less standard deviat
mean median cytokin concentr across test antigen
vaccin develop inform regard ex vivo immun activ acquir
relev neoantigen select ad vaccin relev neoantigen detect
antigen yield respons given highest prioriti follow antigen yield
strongest immun respons person vaccin compos immuno-stimulatori synthet long peptid pair
adjuv poly-iclc formul ship directli clinic site administ poly-iclc
immunostimul activ multipl element host defens use vaccin adjuv optim
antigen-specif immun vaccin contain uniqu peptid use
synthet peptid allow rapid product vaccin gmp-compliant manner well deliveri
effect dose neoantigen stimul immun respons genocea believ needle-to-needl vaccin
gener time approxim week compar current competitor genocea
progress clinic develop initi part phase i/iia studi
patient sever differ tumor type evid diseas high risk relaps part b/c
studi proceed includ patient advanc metastat solid tumor receiv monotherapi
combin therapi first immunogen data trial expect
 et al improv cancer immunotherapi empir neoantigen select trend cancer
 salazar vaccin adjuv use poly- deriv expert review vaccin pp
potenti synergi neoantigen vaccin checkpoint inhibitor
inhibitor merck nyse keytruda pembrolizumab bristol-my squibb nyse
opdivo nivolumab work block interact also target pd-
key immun checkpoint often prevent cell nk cell tumor associ macrophag
recogn attack tumor cell class therapeut develop immuno-oncolog backbon
treatment target axi keytruda opdivo demonstr activ across wide rang
cancer indic includ melanoma nsclc renal cell carcinoma rcc hepatocellular carcinoma
urotheli carcinoma other cumul sale drug class roughli billion
market expect expand therapi becom cornerston treatment sever cancer respons
inhibit vari cancer type although key predictor respons resist shown figur
figur predictor respons resist inhibit
predictor respons
high level tumor infiltr
high mutat burden
high mhc
level neg immun
regulatori cell tumor
predictor resist
decreas number til
inabl t-effector lymphocyt
recogn tumor cell
down-regul
high level neg immun
regulatori cell tumor
immun checkpoint inhibitor ici therapi regard remov brake immun system
howev effect elimin cancer cell must also accompani recognit cancer foreign
adapt immun system neoantigen capabl teach adapt immun system recogn tumor
cell specif antigen express normal host tissu provid good rational
develop neoantigen/ici combin therapi previous conduct pre-clin studi shown
neoantigen enhanc respons therapi murin model
genocea current develop combin treatment therapi multipl tumor
type use intend increas number tumor direct cell tumor
microenviron enhanc abil t-effector lymphocyt recogn attack tumor cell
potenti therapeut benefit co-administr ici neoantigen vaccin indic
preliminari clinic data use predict algorithm form privat neon ntgn
howev due issu regard predict accuraci limit type immun respons gener
note platform appear less robust atla
et al role neoantigen respons immun checkpoint blockad intern immunolog pp
establish atla platform pre-clin model murin melanoma cell line inject
follow tumor spleen collect mice tumor cell line normal
tissu subject whole exom sequenc somat mutat identifi synthes dna
transform coli cllo cell screen mous mddc incub individu bacteri
clone subsequ cultur cell sort spleen tumor-bear mice cytokin
secret measur meso scale discoveri msd assay workflow studi design present figur
figur atla studi design mous
msd screen plate cytokin model fit log-transform data mean respons
control protein subtract averag respons candid neoantigen data normal
cytokin concentr interpret standard deviat control point
plot figur deem stimulatori least standard deviat normal
cytokin respons control protein red point repres inhibitori respons least
standard deviat normal control cytokin respons point fell within standard deviat
normal cytokin respons control protein deem non-respons antigen
starobinet et al ex vivo atlas-identif neoantigen person cancer immunotherapi mous
melanoma poster present american associ cancer research confer chicago illinoi april
figur atla cell respons neoantigen
result atla platform screen compar predict neoantigen use algorithm
predict bind affin peptid sequenc two mhc molecul figur
predict total neoantigen antigen identifi stimulatori
identifi inhibitori antigen atla platform atla platform identifi addit
antigen stimulatori antigen inhibitori mhc-bind predict algorithm fail identifi
major atlas-identifi stimulatori neoantigen predict neoantigen fail elicit
respons atla platform overal result indic atla platform confirm known
antigen also identifi stimulatori inhibitori antigen incorpor inform
genocea product candid could lead better immun respons seen mani predict
algorithm although compel addit studi need confirm proof concept atla platform
mous atla model current use evalu therapeut impact atlas-identifi inhibitori
figur comparison atla algorithm predict model
clinic data discuss
second quarter genocea announc initi part phase i/iia trial evalu
safeti immunogen patient sever type solid tumor prior initi
trial genocea conduct multitud immun profil studi across varieti cancer demonstr
valid atla platform neoantigen select compani demonstr superior atla
one predict algorithm netmhcpan fail predict stimulatori neoantigen identifi
atla addit stronger t-cell respons note novel antigen compar tradit use
taa support rational util atla identif novel neoantigen increas therapeut
on-going phase i/iia clinic trial genocea announc accept ind may
follow enrol first patient phase i/ii clinic trial june studi consist
three part shown figur part administ monotherapi least patient solid
tumor evid diseas high risk relaps patient enrol immedi
follow tumor resect vaccin contain confirm neoantigen per peptid
patient vaccin fix schedul vaccin day day day booster shot
week week week conting posit initi safeti immunogen result part part
b/c initi parallel light recent data regard effect baselin corticosteroid use efficaci
ici studi requir patient steroid-fre time sampl collect vaccin
part evalu combin ici patient stabl disease/parti respons patient
enrol start ici therapi vaccin gener group three group time vaccin
readi stabl disease/parti respons receiv vaccin continu ici therapi individu
exhibit diseas progress receiv standard care complet respons option
requir receiv part studi evalu safeti efficaci
monotherapi advanc metastat diseas immunogen data part anticip
figur overview phase i/iia studi
immun profil data patient varieti solid tumor neoantigen screen perform
individu varieti solid tumor demonstr abil atla identifi biolog relev
cell neoantigen screen conduct individu differ tumor type
mutat burden rang mutat atla abl gener empir identif neoantigen
independ hla-typ without predict effect address limit current silico approach
netmhcpan current predict algorithm fail predict true neoantigen fail predict
true neoantigen comparison atla netmhcpan neoantigen identif
result cell shown figur
figur comparison neoantigen identif atla netmhcpan
addit identif stimulatori neoantigen atla abl predict inhibitori antigen
cell identifi use silico approach netmhcpan shown mischaracter
inhibitori neoantigen neoantigen stimul t-cell respect atla
analysi highlight distinct neoantigen demonstr fewer
neoantigen share two t-cell subset analysi look mutant allel frequenc gene
express mutat type give insight predict mutat would elicit t-cell respons
profil t-cell respons patient colorect carcinoma t-cell profil conduct across
popul health individu individu colorect carcinoma adenomat polyp healthi
patient popul consist individu popul patient adenomat polyp
individu individu includ present early-stag diseas present
late-stag diseas shown figur popul demonstr strong enrich
t-cell respons subset tumor-associ antigen taa approxim patient exhibit
 et al empir neoantigen identif use atla platform across thousand mutat
multipl tumor type highlight advantag algorithm predict method aacr abstract
stimulatori t-cell respons two taa approxim patient exhibit stimulatori
t-cell respons two taa measur interferon- ifn-
figur taa-induc stimulatori respons patient popul
establish cytokin t-cell respons popul specif taa deem statist signific
compar healthi individu taa-specif respons also determin independ
diseas stage demonstr compar level stimulatori respons across early-stag late-stag cohort
t-cell subset
profil taa-induc t-cell respons lung cancer patient genocea conduct proof-of-concept
studi appli atla technolog platform profil t-cell respons divers sampl taa gene
deriv lung-canc patient analysi conduct across lung-canc patient undergo
ici treatment either nivolumab pembrolizumab stimulatori respons defin achiev cytokin
concentr exceed median absolut deviat neg control inhibitori respons
defin achiev cytokin concentr fall median absolut deviat neg control
patient demonstr stimulatori respons t-cell
patient demonstr inhibitori respons t-cell subset frequenc
stimulatori respons rang t-cell t-cell
shown figur ifn- respons two novel taa stronger respons seen three taa
commonli use lung-canc vaccin atla demonstr flexibl
 et al t-cell respons profil colorect carcinoma patient reveal enrich respons
 et al profil t-cell respons tumor-associ antigen lung cancer patient treat
identifi novel target well-studi realm tumor-associ antigen show potenti gener
treatment higher efficaci major profil taa demonstr stimulatori t-cell respons
taa induc stimulatori respons t-cell subset discoveri stronger
t-cell respons novel taa compar taa tradit util lung cancer-vaccin highlight
potenti increas therapeut valu use atlas-identifi neoantigen
figur stronger respons note atla novel taa compar previous describ
profil taa-induc t-cell respons melanoma patient blood sampl patient collect
test full-length melanoma tumor-associ antigen taa gene taa-gen express coli
librari test use participant-deriv mddc participant-deriv t-cell patient
checkpoint inhibitor respond simultan gener respons t-cell t-cell
analysi respons show may predict respons checkpoint inhibitor depict
figur patient non-respond cohort display minim discern respons measur
concentr varieti differ cytokin
figur activ predictor checkpoint inhibitor blockad respons
 et al specif t-cell respons tumor-associ antigen melanoma patient undergo immun
ifn -- secret t-cell also show potenti predict respons immun checkpoint blockad therapi
non-respond cohort show undetect level ifn- t-cell subset addit analysi
respons frequenc gene t-cell subset domin taa respons detect
suggest heterogen immun respons variou tumor-associ antigen would significantli limit
efficaci share antigen vaccin
market inform immuno-oncolog
checkpoint inhibitor bristol-my squibb opdivo yervoy merck keytruda becom import
treatment option sever form cancer although effect compar convent therapi mani patient
respond treatment option limit follow progress respons rate inhibitor
approv indic present figur repres sizeabl market opportun
respons rate base prescrib label pivot trial public opdivo keytruda pfizer bavencio
figur respons rate approv indic
unresect metastat melanoma
first-lin nsclc express
chemotherapi keytruda advanc nsclc
relaps progress classic hodgkin lymphoma
hsct
local advanc metastat urotheli carcinoma
unfit cisplatin-chemotherapi
recurr metastat cervic cancer
includ monotherapi combin
combin
market opportun combin agent highlight nektar/bristol-my squibb collabor
due vast-numb patient benefit checkpoint inhibitor great interest
pharmaceut compani investor combin agent highlight collabor
bristol-my squibb announc earli
receptor beta subunit bias agonist preliminari phase i/ii data show
encourag respons rate treatment nave melanoma nsclc treatment nave rcc treatment nave
urotheli carcinoma includ neg tumor importantli notabl increas til
immunosuppress regulatori cell contain tumor peripheri therebi allow immunotherapi
combin maintain durabl effect follow earli data bristol-my squibb enter global
develop commerci collabor nektar term agreement
nektar receiv up-front payment billion cash stock elig receiv
addit billion mileston compani share global profit nektar receiv
develop cost also share two compani evalu combin
opdivo indic tumor type size collabor give indic premium
big pharma will pay novel immuno-oncolog therapi
high level interest neoantigen approach big pharma highlight larg collabor
compani privat genentech vtx rog vx merck nyse
privat janssen nyse advaxi adx
term deal other shown figur current vaccin
develop program span differ antigen-select method well differ deliveri method includ rna-
deliveri peptide-deliveri figur show overview compet neoantigen vaccin compani
descript approach although genocea current collabor larg pharma
compani note publicli explor partnership opportun atla platform
partner janssen receiv
up-front
expand anoth up-front
develop
partner
up-front equiti invest
elig mileston
royalti
partner genentech
up-front near-term mileston
initi partner merck
up-front invest
expand
up-front invest elig
tier royalti
partner bluebird bio
up-front equiti invest
partner
up-front equiti invest
elig receiv
develop commerci
mileston also partner
boehring ingelheim up-front
elig mileston
royalti
predict algorithm develop base exist method could defici
major current neoantigen vaccin develop still reli silico antigen select method method
associ posit predict valu due complex heterogen across mhc
predict valu lower mhc ii bind owe increas length mhc ii
epitop algorithm-method conting train neural network make predict base underli
databas gener restrict peptid known bind affin howev
distinct mhc allel human popul uniqu peptid affin databas record
fraction divers neoantigen landscap although neon algorithm util cell engin express singl
hla allel provid better understand specif mhc molecul singl allele-resolut still
restrict class hla-pres peptid mean mainli identifi neoantigen potenti stimul
 et al improv cancer immunotherapi empir neoantigen select trend cancer
result algorithm hla-restrict like limit predict efficaci addit
lack measur experiment data algorithm method base predict singl mhc bind event
fail take account step involv antigen present includ peptid transport antigen
process therefor relianc predict neoantigen-select lead incorpor irrelev
incorpor neoantigen pre-exist immun respons offer potenti
clinic advantag key differenti factor atla platform antigen select base direct test
ex-vivo model patient immun system deliv possibl neoantigen directli patient
antigen present cell apc atla allevi concern antigen process transport associ
algorithm method neoantigen select base strength immun respons gener direct
test autolog cell allow genocea build person vaccin consist
neoantigen pre-exist immun respons greatli increas probabl translat benefici immun
genocea advanc competitor neon gener modest immun respons
like result inaccur predict method announc data clinic trial enrol
cancer patient recent histori recurr diseas high risk relaps note underli
algorithm compani predict model undisclos although detect respons
predict neoepitop ex vivo approxim predict neoantigen success gener
detect immun respons blood without vitro predict t-cell stimul
less accur predict high-affin antigen gener respons addit t-cell
respons detect neoantigen algorithm poor predict bind score neon
report similar efficaci result trial enrol melanoma patient t-cell respons detect
predict neoantigen t-cell respons detect predict neoantigen
respons rate rise one round pre-stimul howev patient complet vaccin
demonstr autolog tumor recognit neoantigen-specif t-cell
atla uniqu abil identifi inhibitori antigen current predict algorithm reli
bind affin capabl classifi antigen either inhibitori stimulatori
method inhibitori antigen seen true sole bind event detect lead potenti
incorpor irrelev neoantigen treatment howev label neoantigen inhibitori
stimulatori depend effect impart t-cell post-bind genocea atla platform may solut
measur individu autolog t-cell respons cytokin concentr variou potenti neoantigen
antigen result cytokin concentr decreas establish threshold detect inhibitori
genocea current begin pre-clin work therapeut impact newli identifi inhibitori
therapeut benefit neoantigen shown promis improv antigen select may
boost efficaci although neon opinion flaw antigen select
method illustr potenti clinic benefit neoantigen patient demonstr detect
 et al mass spectrometri profil hla-associ peptidom mono-allel cell enabl
et al person rna mutanom vaccin mobil poly-specif therapeut immun cancer natur
immun respons patient enrol biontech studi remain recurr free entireti
follow-up period patient complet vaccin neon studi remain
recurr free well patient relaps within biontech studi patient develop neoepitope-
vaccin relat clinic respons develop metastat lesion demonstr complet respons
signific partial respons vaccin patient neon studi gener epitop spread highlight
capac neoantigen stimul immun system even beyond peptid includ treatment patient
across trial exhibit persist neoantigen-specif t-cell month post-treat display potenti
prolong therapeut benefit studi also support rational combin ici therapi
neoantigen vaccin overal patient across studi relaps initi therapi
vaccin demonstr complet respons treatment complet respons rate
gener genocea believ main driver demonstr superior efficaci compar
competitor increas accuraci neoantigen select proprietari atla platform
ici combin therapi develop
follow initi approv checkpoint inhibitor field immunotherapi drug develop quickli
grown combin studi on-going checkpoint inhibitor approv
immunotherapi combin treatment involv therapi melanoma renal cell
carcinoma chemotherapi lung cancer sever treatment develop combin
checkpoint inhibitor select one interest list figur notabl therapi
administ intratumor inject could limit use invas tumor
figur select combin treatment develop
mechan
phase
multi-tki
class iv
primarili
sq ip multipl tumor
atla opportun develop
genocea expect advanc next-gener person cancer vaccin util innov
deliveri modal near futur atla platform also identifi target tumor-associ antigen
taa vaccin viru associ antigen vaa t-cell receptor tcr develop current
genocea also announc initi work person t-cell therapi develop
base identif relev person neoantigen therapi work t-cell grown
autolog pbmc collect patient present potenti advantag current t-cell therapi solid
tumor expans t-cell target neoantigen tradit use taa pose advantag gener
t-cell elicit enhanc immun respons subject central peripher toler
therapeut vaccin herp
phase iii-readi investig t-cell direct immunotherapi treatment genit herp
infect treatment design use compani proprietari atla platform profil t-cell
respons mount human infect compos antigen
matrix-m adjuv in-licens inc approxim world
popul one herp simplex unit state preval
preval current commercially-avail vaccin cure genocea
believ address larg unmet clinic need within patient popul
septemb compani report result phase iib studi phase ii trial
conduct evalu potenti phase endpoint dose subject enrol random three
dose groups- placebo per adjuv per adjuv subject receiv
three inject interv studi met primari endpoint demonstr statist
signific reduct rate viral shed per adjuv cohort genocea later
report per adjuv cohort also demonstr signific reduct median
genit lesion rate demonstr favor safeti profil throughout studi seriou treatment-
relat advers event low rate discontinu due advers event
genocea current explor strateg altern ceas spend activ
program announc strateg shift immuno-oncolog
genocea proprietari atla platform protect three patent famili first famili consist two us-
grant patent one pend patent cover fundament applic platform develop darren
higgin phd licens harvard univers first patent famili expir june second
expir decemb second patent famili includ three issu one pend us patent foreign
applic genocea uniqu applic platform offer protect least possibl
extens third patent famili pend patent issu famili would expir march
presid chief execut offic
william clark serv genocea presid chief execut offic sinc februari previous
serv chief busi offic august februari mr clark serv genocea board
et al persist population- epidemiolog transmiss herpesvirus biolog therapi
immunoprophylaxi chapter
 et al seropreval herp simplex viru type unit state journal infecti
director sinc februari prior join compani serv chief busi offic vanda
pharmaceut inc vanda biopharmaceut compani co-found vanda led
compani strateg busi develop activ play central role rais million
multipl public privat financ prior vanda mr clark princip capit llc ventur
capit firm invest biopharmaceut compani serv varieti commerci strateg role
smithklin beecham glaxosmithklin mr clark hold harvard univers
wharton school univers pennsylvania
pamela carrol ph join genocea lead immuno-oncolog effort bring expertis cancer
biolog immuno-oncolog develop strateg direct genocea oncolog program
previou posit includ vice presid oncolog discoveri roch pharma research earli develop
vice presid janssen oncolog johnson johnson innov found head research belfer
institut appli cancer scienc dana farber cancer institut dr carrol develop drug discoveri
experi bristol-my squibb appli genom merck research laboratori oncolog dr carrol
earn biolog st michael colleg vermont doctor cellular biolog stoni brook
univers post-doctor fellowship stanford univers
jessica baker flechtner ph join genocea soon compani found current serv
chief scientif offic dr flechtner pioneer develop novel vaccin direct toward cell
immun year experi immunolog infecti diseas cancer vaccin
develop lead genocea effort develop cell-direct vaccin immunotherapi infecti
diseas indic prior join genocea dr flechtner develop vaccin immunotherapi
cancer infecti diseas autoimmun allergi sever compani includ mojav therapeut
antigen inc inventor ten pend four issu patent multipl peer-
review scientif public dr flechtner perform post-doctor work dana farber cancer institut
harvard medic school hold ph cellular immunolog anim scienc cornel
univers member american associ immunologist american associ cancer
research societi immunotherapi cancer american societi microbiolog
prior join genocea eric vice presid corpor busi develop program manag
commerci oper inc acquisit merck august eric also held
role investor relat corpor commun whilst idenix prior idenix eric spent four year
biogen idec investor relat busi develop role spent six year wall street equiti
research analyst morgan schwab soundview capit market bear stearn start wall street
post-doctor research scientist depart immunobiolog guy hospit london
studi cell develop author sever book chapter peer-review paper includ
cell immun gene develop hold ph immunobiolog yale univers
biolog triniti univers
svp pharmaceut scienc manufactur
narind singh join genocea march current serv senior vice presid pharmaceut scienc
manufactur mr singh year experi process develop scale-up technic
oper manufactur suppli chain biopharmaceut prior join genocea mr singh vice
presid drug product develop manufactur built integr
drug product group support momenta expand portfolio biosimilar novel biolog pipelin prior
momenta mr singh play key role develop biolog base pipelin
commerci drug product strong focu process develop commerci manufactur
new technolog develop mr singh hold tech/m tech biochem engin
indian institut technolog delhi chemic engin univers houston
 ucla anderson school manag
risk invest
consid invest genocea high-risk invest genocea develop stage compani
histori take treatment market current fda approv drug portfolio
sever compani tri target indic genocea cancer treatment pipelin
especi crowd competitor genocea lead program yet gener pivot data limit clinic
data date furthermor earli indic efficaci necessarili translat posit late-stag result
compani genocea may unabl obtain suffici capit fund plan develop program
regulatori risk associ develop drug genocea may receiv fda approv
candid despit signific time financi invest regulatori approv market sell drug
guarante drug penetr market sale may meet expect investor
research analyst denot ac cover report certifi multipl research analyst primarili respons
report research analyst denot ac cover within document individu certifi respect
secur subject compani research analyst cover research view express report accur
reflect person view subject secur subject compani part research
analyst compens directli indirectli relat specif recommend view express research
analyst report
